Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference

CAMBRIDGE, MA – July 31, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that company President and Founder, John Knopf, Ph.D., will provide a corporate presentation at the 27th Annual Canaccord Adams Global Growth Conference on Tuesday August 7, 2007 at 1:30 pm (EDT). The conference will be held at the Intercontinental Boston Hotel in Boston, MA.

About Acceleron Pharma

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factors (GDFs) and Bone Morphogenetic Proteins (BMPs). ACE-011, an anabolic bone agent, is the company’s lead program, and is being developed to reverse bone loss in diseases such as cancer-related bone loss and osteoporosis. In addition, the company is advancing through preclinical development with product candidates that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.

Contact: Steven Ertel, Vice President, Corporate Development, Acceleron Pharma, tel: 617-520-1334 and Maureen Suda (Media) Suda Communications, tel: 585-387-9248.

BACK TO PRESS RELEASES